Spruce Biosciences, Inc.
corporate_fare Company Profile
Spruce Biosciences, Inc. (NASDAQ:SPRB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for SPRB at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- FDA BLA for Sanfilippo Drug on Track for Q4 2026; Spruce Biosciences Secures $50M Capital
- Carlyle Group/Abingworth Reduces Stake Below 5% in Spruce Biosciences
- Spruce Biosciences Reports Positive Long-Term Clinical Data for TA-ERT in Sanfilippo Syndrome Type B, Paving Way for FDA Approval
- Spruce Biosciences Secures Up to $50M Debt Facility with Warrants to Extend Runway
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$38.97M
Diluted EPS
-$50.83
Op. Cash Flow
-$33.33M
Operating Income
-$36.51M
Cash & Equivalents
$48.91M
Total Debt
$0
Debt / Equity
0.00×
Shares Outstanding
1.37M sh
Source: 10-K · filed 2026-03-09 · accession 0001193125-26-097558
show_chartPrice Chart
Loading chart...
feed SPRB - Filings & News (Page 2)
SPRB
Mar 09, 2026, 7:05 AM EDT
Price at Filing:
$58.00
Real-time Price:
$38.00
Change:
-$20.00 (-34%)
Market Cap:
$109.212M
SPRB
Feb 18, 2026, 5:27 PM EST
Price at Filing:
$53.76
Real-time Price:
$38.00
Change:
-$15.76 (-29%)
Market Cap:
$109.212M
SPRB
Feb 05, 2026, 4:11 PM EST
Price at Filing:
$70.85
Real-time Price:
$38.00
Change:
-$32.85 (-46%)
Market Cap:
$109.212M
SPRB
Jan 08, 2026, 8:05 AM EST
Price at Filing:
$78.10
Real-time Price:
$38.00
Change:
-$40.10 (-51%)
Market Cap:
$109.212M